Le Lézard
Classified in: Health
Subjects: LAW, HSP, FVT

If you purchased Infants' Tylenol, you may be entitled to cash from a class action settlement


LOS ANGELES, Dec. 16, 2019 /PRNewswire/ -- Milstein, Jackson, Fairchild & Wade, LLP of Los Angeles, CA and Heideman Nudelman & Kalik, PC of Washington, DC announce that a proposed settlement has been reached with Johnson & Johnson Services, Inc. and Johnson & Johnson Consumer Inc. ("JJCI") about the packaging of Infants' Tylenol. The plaintiffs in the lawsuit claim that the Infants' Tylenol packaging (the text "Infants" and a picture of a mother holding her baby) deceives consumers into believing Infants' Tylenol is unique/specially formulated for infants, when the bottle contains liquid acetaminophen of the same concentration in Children's Tylenol, and therefore causes consumers to overpay for Infants' Tylenol. JJCI denies all the plaintiffs' allegations of deception, and asserts that the safety features of Infants' Tylenol, especially the accompanying syringe for safe dosing of very young children, means Infants' and Children's are different products. The settlement is not an admission of wrongdoing.

You are included in the settlement as a "Class Member" if you are in the United States and bought Infants' Tylenol at any time for personal or household use between October 3, 2014 and January 6, 2020.

A $6.315 million fund will be created, and JJCI has agreed to injunctive relief. After deducting administrative costs, Class Counsel's attorneys' fees and expenses, and service awards for the named plaintiffs, the balance will be used to pay Class Member claims. Class Members may claim $2.15 for every bottle of Infants' Tylenol purchased up to a maximum of 7 bottles ($15.05) without proof of purchase or an unlimited number of bottles with proof of purchase. You must submit a Claim Form by April 13, 2020, to receive a settlement payment.

If you are a Class Member and do not submit a Claim Form, your rights will be affected but you will not get a settlement payment. If you do not want to be legally bound by the settlement, you must exclude yourself from it by April 13, 2020. If you stay in the settlement (do not exclude yourself), you may object to the settlement by April 13, 2020.

For more information, go to www.InfantsTylenolSettlement.com or call 1-866-458-2108.
Elkies v. Johnson and Johnson Services, Inc., Case No. 2:17-cv-07320 (C.D. Cal.).

SOURCE Milstein, Jackson, Fairchild & Wade, LLP


These press releases may also interest you

at 08:20
Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced it has launched its Laboratory Automation Provider Program, enabling automation providers to readily support the adoption of Parse's...

at 08:15
Seed Health, a microbiome science company, today announced the appointment of Zain Kassam, M.D., M.P.H., as Chief Medical Officer. An award-winning physician-scientist, Dr. Kassam has played a pivotal role in the advancement of microbiome science for...

at 08:10
bioAffinity Technologies, Inc. , a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer and other lung diseases, today announced David Elzi, Ph.D., has been named Vice President of...

at 08:10
Amneal Pharmaceuticals, Inc. ("Amneal" or the "Company") today announced the availability of Over the Counter ("OTC") Naloxone Hydrochloride (Naloxone HCI) Nasal Spray, USP, 4mg, following Abbreviated New Drug Application ("ANDA") approval from the...

at 08:10
BigHat Biosciences, a biotechnology company with an artificial intelligence/machine learning-guided antibody discovery and development platform announced a collaboration with Janssen Biotech Inc., a Johnson & Johnson company. This strategic...

at 08:10
Kiromic BioPharma, Inc. ("Kiromic" or the "Company") announces consistent favorable safety, tolerability, and efficacy from follow-up visits of the first cohort of three patients enrolled in the Company's Deltacel-01 Phase 1 clinical trial....



News published on and distributed by: